Castor Oil Liquid
NDC Package 69452-487-97
Package Information
Castor Oil liquids is preferably take on an empty stomach. This formulation utilizes a liquid delivery system. Marketed by Bionpharma Inc., this product is identified by NDC 69452-487 and is authorized under FDA application M007.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69452 - Bionpharma Inc.
- 69452-487 - Castor Oil
- 69452-487-97 - 177 mL in 1 BOTTLE
- 69452-487 - Castor Oil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69452-487-97 identifies a specific commercial package of 177 ml in 1 bottle of Castor Oil, a human over the counter drug labeled by Bionpharma Inc.. This liquid is formulated for oral use and contains castor oil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bionpharma Inc. on October 06, 2025. The current certification is valid through December 31, 2026.
How is this Bionpharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69452048797. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.